Rapid neurological deterioration in a patient with multiple sclerosis treated with systemic interleukin-2 and interferon-alpha 2b for metastatic renal cell carcinoma.

Eitemau Tebyg

• Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma.
  gan: Ravaud, A., et al.
  Cyhoeddwyd: (1994)
• A randomized phase II trial of interleukin 2 and interleukin 2-interferon alpha in advanced renal cancer.
  gan: Jayson, G. C., et al.
  Cyhoeddwyd: (1998)
• Final report of a phase II study of interleukin 2 and interferon alpha in patients with metastatic melanoma.
  gan: Kruit, W. H., et al.
  Cyhoeddwyd: (1995)
• Rapid deterioration in quality of life during interleukin-2- and α-interferon-based home therapy of renal cell carcinoma is associated with a good outcome
  gan: Atzpodien, J, et al.
  Cyhoeddwyd: (2003)
• Thyroiditis after treatment with interleukin-2 and interferon alpha-2a.
  gan: Pichert, G., et al.
  Cyhoeddwyd: (1990)